Abstract
Background: The most potent angiogenic factor is the vascular endothelial growth factor (VEGF), and CD34 is an endothelial antigen that has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoangiogenesis. In the present study we report that VEGF expression and its relationship with MVD, in poorly and well differentiated colon adenocarcinoma, in order to consider the possibility of using the correlation between both antibodies as a prognostic factor. Materials and Methods: Tumor sections were stained by immunohistochemistry for CD34 and VEGF. Results: The mean of VEGF and CD34 did not show any significant differences between both types of tumors. Conclusion: The conventional factors taken into consideration were not significantly related to the angiogenic factors examined, so we could affirm that the correlation of both markers could be useful as prognostic factor.
Keywords: Colon cancer, VEGF, CD34, angiogenesis, colon, adenocarcinoma
Current Chemical Biology
Title: Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer
Volume: 3 Issue: 3
Author(s): Ana Maria Inda, Marcela Nilda Garcia, Laura Beatriz Andrini, Adriana Laura Garcia, Ayelen Fernandez Blanco, Cecilia Cristina Furnus, Susana Mercedes Galletti, Javier Brandoni, Jorge Guillermo Martinez, Guillermo Daniel Prat and Ana Lia Errecalde
Affiliation:
Keywords: Colon cancer, VEGF, CD34, angiogenesis, colon, adenocarcinoma
Abstract: Background: The most potent angiogenic factor is the vascular endothelial growth factor (VEGF), and CD34 is an endothelial antigen that has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoangiogenesis. In the present study we report that VEGF expression and its relationship with MVD, in poorly and well differentiated colon adenocarcinoma, in order to consider the possibility of using the correlation between both antibodies as a prognostic factor. Materials and Methods: Tumor sections were stained by immunohistochemistry for CD34 and VEGF. Results: The mean of VEGF and CD34 did not show any significant differences between both types of tumors. Conclusion: The conventional factors taken into consideration were not significantly related to the angiogenic factors examined, so we could affirm that the correlation of both markers could be useful as prognostic factor.
Export Options
About this article
Cite this article as:
Inda Maria Ana, Garcia Nilda Marcela, Andrini Beatriz Laura, Garcia Laura Adriana, Blanco Fernandez Ayelen, Furnus Cristina Cecilia, Galletti Mercedes Susana, Brandoni Javier, Martinez Guillermo Jorge, Prat Daniel Guillermo and Errecalde Lia Ana, Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer, Current Chemical Biology 2009; 3 (3) . https://dx.doi.org/10.2174/2212796810903030302
DOI https://dx.doi.org/10.2174/2212796810903030302 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery New Target Therapies for Brain Metastases from Breast Cancer
Current Cancer Drug Targets Treatment Directed to Signalling Molecules in Patients with Advanced Differentiated Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer
Current Drug Targets Gold Nanoparticles as Carrier(s) for Drug Targeting and Imaging
Pharmaceutical Nanotechnology Integrins as Therapeutic Targets for Respiratory Diseases
Current Molecular Medicine Tissue Biomarkers for Prostate Cancer Radiation Therapy
Current Molecular Medicine Synthesis, Preferentially Hypoxic Apoptosis and Anti-Angiogenic Activity of 3- Amino-1,2,4-Benzotriazine-1,4-Dioxide Bearing Alkyl Linkers with a 3-Amino-1,2,4- Benzotriazine-1-Oxide Moiety
Anti-Cancer Agents in Medicinal Chemistry Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents A Comprehensive Review on Nanotechnology-Based Innovations in Topical Drug Delivery for the Treatment of Skin Cancer
Current Pharmaceutical Design Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Anticancer Potential of Aguerin B, a Sesquiterpene Lactone Isolated from <i>Centaurea behen</i> in Metastatic Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery The Adjunctive Value of Diffusion Weighted Imaging in Diagnosis and Follow Up of Uterovaginal Diffuse B-cell Lymphoma: A Case Report and Literature Review
Current Medical Imaging Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals Electroporation Gene Therapy Preclinical and Clinical Trials for Melanoma
Current Gene Therapy Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Malignant Mesothelioma: Cell Survival Pathways and Radiation Therapy
Current Respiratory Medicine Reviews Erlotinib: A Targeted Anticancer Drug
Current Cancer Therapy Reviews